PharmGKB summary: oxycodone pathway, pharmacokinetics.
作者信息
Huddart Rachel, Clarke Melissa, Altman Russ B, Klein Teri E
机构信息
Departments of Biomedical Data Sciences.
Medical Home Development Group, Washington, District of Columbia.
出版信息
Pharmacogenet Genomics. 2018 Oct;28(10):230-237. doi: 10.1097/FPC.0000000000000351.
Abstract
摘要
相似文献
1
PharmGKB summary: oxycodone pathway, pharmacokinetics.药物基因组学知识库总结：羟考酮途径、药代动力学。
Pharmacogenet Genomics. 2018 Oct;28(10):230-237. doi: 10.1097/FPC.0000000000000351.
2
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].[癌症疼痛患者中阿片类镇痛药的药代动力学处置及临床反应的个体间差异]
Yakugaku Zasshi. 2015;135(5):709-15. doi: 10.1248/yakushi.14-00234-4.
3
The pharmacokinetics of oxycodone.羟考酮的药代动力学。
J Pain Palliat Care Pharmacother. 2004;18(4):17-30. doi: 10.1300/j354v18n04_03.
4
Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.个性化羟考酮给药：利用药物遗传学检测和临床药代动力学降低毒性风险并提高疗效。
Pain Med. 2014 May;15(5):723-5. doi: 10.1111/pme.12417. Epub 2014 Mar 17.
5
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.斯普拉格-道利大鼠体内羟考酮的药代动力学、氧化代谢及口服生物利用度的性别差异
Clin Exp Pharmacol Physiol. 2008 Mar;35(3):295-302. doi: 10.1111/j.1440-1681.2007.04821.x. Epub 2007 Oct 31.
6
Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.个体化羟考酮剂量调整：运用药物遗传学检测和临床药代动力学降低毒性风险并提高疗效。
Pain Med. 2014 May;15(5):791-806. doi: 10.1111/pme.12380. Epub 2014 Feb 12.
7
[The blood-brain barrier transport mechanism controlling analgesic effects of opioid drugs in CNS].[控制阿片类药物在中枢神经系统中镇痛作用的血脑屏障转运机制]
Yakugaku Zasshi. 2015;135(5):697-702. doi: 10.1248/yakushi.14-00234-2.
8
Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.性别差异与处方阿片类药物滥用：以羟考酮和氢可酮为例。
Pharmacol Res. 2016 Jun;108:31-38. doi: 10.1016/j.phrs.2016.04.012. Epub 2016 Apr 20.
9
Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.利尿剂是否具有抗伤害感受作用：螺内酯、依普利酮、呋塞米和氯噻嗪单独及与羟考酮和吗啡联用的研究
Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):38-45. doi: 10.1111/bcpt.12634. Epub 2016 Jul 21.
10
Population pharmacokinetics of oxycodone in patients with cancer-related pain.癌症相关疼痛患者中羟考酮的群体药代动力学
J Pain Palliat Care Pharmacother. 2012 Sep;26(3):220-5. doi: 10.3109/15360288.2012.702200.
引用本文的文献
1
Persistent Transcriptome Alterations in Zebrafish Embryos After Discontinued Opioid Exposure.阿片类药物暴露停止后斑马鱼胚胎中持续的转录组改变。
Int J Mol Sci. 2025 May 19;26(10):4840. doi: 10.3390/ijms26104840.
2
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.脑细胞色素P450：探索神经健康与代谢调节
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
3
Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?细胞色素P450 2D6（CYP2D6）基因分型是否会影响癌症患者的羟考酮剂量、药代动力学、疼痛及不良反应？
Pharmacogenomics. 2024;25(14-15):579-586. doi: 10.1080/14622416.2024.2430161. Epub 2024 Dec 4.
4
Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications.口服纳曲酮治疗期间阿片类药物阳性尿液药物筛查及其临床意义。
Ment Health Clin. 2024 Apr 1;14(2):102-106. doi: 10.9740/mhc.2024.04.102. eCollection 2024 Apr.
5
Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone.药物遗传学特征对布洛芬和羟考酮用于小儿疼痛缓解及不良事件的影响。
Pain Rep. 2023 Oct 17;8(6):e1113. doi: 10.1097/PR9.0000000000001113. eCollection 2023 Dec.
6
Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.重要的细胞色素 3A4 和 2D6 介导的药物-药物相互作用在因髋部骨折住院的老年患者中对羟考酮的消耗：一项横断面研究。
Aging Clin Exp Res. 2023 Nov;35(11):2471-2481. doi: 10.1007/s40520-023-02569-7. Epub 2023 Oct 20.
7
Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.氢可酮、羟考酮和吗啡的代谢与药物相互作用。
J Pharmacol Exp Ther. 2023 Nov;387(2):150-169. doi: 10.1124/jpet.123.001651. Epub 2023 Sep 7.
8
The Pharmacological Treatment of Chronic Pain: From Guidelines to Daily Clinical Practice.慢性疼痛的药物治疗：从指南到日常临床实践
Pharmaceutics. 2023 Apr 6;15(4):1165. doi: 10.3390/pharmaceutics15041165.
9
Improving the Emergency Department Management of Sickle Cell Vaso-Occlusive Pain Crisis: The Role and Options of Sublingual and Intranasally Administered Analgesia.改善镰状细胞血管阻塞性疼痛危象的急诊科管理：舌下和鼻内给药镇痛的作用及选择
J Clin Med Res. 2023 Jan;15(1):10-22. doi: 10.14740/jocmr4841. Epub 2023 Jan 24.
10
Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line.评估羟考酮和纳洛酮对 SH-SY5Y 细胞系的神经毒性作用。
Int J Mol Sci. 2023 Jan 11;24(2):1424. doi: 10.3390/ijms24021424.
本文引用的文献
1
The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin.UGT2B7 C802T 和 CYP3A4*1G 多态性对接受奥施康定的癌症患者疼痛缓解的影响。
Support Care Cancer. 2018 Aug;26(8):2763-2767. doi: 10.1007/s00520-018-4130-4. Epub 2018 Mar 3.
2
Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis.一名骨肉瘤合并结核病患者因使用利福平导致羟考酮耐药。
Am J Case Rep. 2017 Oct 24;18:1130-1134. doi: 10.12659/ajcr.905637.
3
Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.与一种已确立的每日两次片剂相比，在健康受试者中给予一种新的每日一次长效片剂制剂后羟考酮的生物利用度。
Int J Clin Pharmacol Ther. 2017 Nov;55(11):881-890. doi: 10.5414/CP203005.
4
Oxycodone for cancer-related pain.羟考酮用于癌症相关疼痛。
Cochrane Database Syst Rev. 2017 Aug 22;8(8):CD003870. doi: 10.1002/14651858.CD003870.pub6.
5
Effects of Single Nucleotide Polymorphisms on Surgical and Postsurgical Opioid Requirements: A Systematic Review and Meta-Analysis.单核苷酸多态性对外科手术及术后阿片类药物需求的影响：一项系统评价与荟萃分析
Clin J Pain. 2017 Dec;33(12):1117-1130. doi: 10.1097/AJP.0000000000000498.
6
CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.小儿外科患者中CYP2D6药物遗传学与羟考酮药代动力学的关联研究
Pharmacogenomics. 2017 Mar;18(4):337-348. doi: 10.2217/pgs-2016-0183. Epub 2017 Feb 17.
7
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.非洲遗传多样性：对细胞色素 P450 介导的药物代谢和药物开发的影响。
EBioMedicine. 2017 Mar;17:67-74. doi: 10.1016/j.ebiom.2017.02.017. Epub 2017 Feb 20.
8
Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.新生儿和婴儿中羟考酮药代动力学的成熟：三项临床试验的群体药代动力学模型
Pharm Res. 2017 May;34(5):1125-1133. doi: 10.1007/s11095-017-2122-6. Epub 2017 Feb 15.
9
Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.新生儿和婴儿中羟考酮药代动力学的成熟：血浆和尿液中的羟考酮及其代谢物。
Br J Clin Pharmacol. 2017 Apr;83(4):791-800. doi: 10.1111/bcp.13164. Epub 2016 Dec 5.
10
Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases.人细胞色素P450和UDP-葡萄糖醛酸转移酶对羟考酮体外代谢的表征
J Pharm Biomed Anal. 2017 Sep 10;144:129-137. doi: 10.1016/j.jpba.2016.09.024. Epub 2016 Sep 26.
Zotero 插件